The recent COVAT study showed that the COVID vaccine, Covishield generates more antibodies and has a higher seropositivity rate than Covaxin. Both vaccines, Covishield and Covaxin, generated a decent response after two doses, according to the research, although Covishield had a much higher seropositivity rate and median anti-spike antibody.

According to preliminary research conducted by Coronavirus Vaccination-induced Antibody Titre (COVAT), Covishield vaccine generated more antibodies than Covaxin. The study, which included healthcare workers (HCW) who had received both doses of either vaccination, also found that seropositivity rates to anti-spike antibody were considerably greater in Covishield recipients than in Covaxin recipients after the first dose.

Both vaccines, Covishield and Covaxin, generated a decent response after two doses, according to the research, although Covishield had a much higher seropositivity rate and median anti-spike antibody.

According to the research,

"The initial doses of Covishield and Covaxin were given to 456 and 96 HCW (325 Male, 227 Female) respectively. After the first dosage, 79.3% of the participants were seropositive. Covishield recipients had a considerably greater responder rate and median (IQR) elevation in anti-spike antibody than Covaxin recipients (84.8 vs. 43.8 percent; 61.5 vs. 6 AU/ml; both p0.001)."

The study included healthcare professionals who had received one of the two vaccinations, Covishield or Covaxin, with/without a history of SARS-CoV-2 infection.

According to the research,

"This current, pan-India, cross-sectional Coronavirus Vaccine-induced Antibody Titre (COVAT) investigation is being carried out among HCW with or without a history of SARS-CoV-2 infection. Anti-spike binding antibody to SARS-CoV-2 is being measured quantitatively at four-time intervals, ranging from 21 days after the first dosage to 6 months after the second dosage."

The study's findings, however, said that both vaccinations induced a good immunological response. "While both vaccinations induced an immunological response, Covishield recipients had considerably greater anti-spike antibody seropositivity rates after the first dose than Covaxin recipients. The ongoing COVAT investigation will shed further insights on the immune response to the second dosage of two vaccinations," researchers said.

Disclaimer- The views and opinions expressed in this article are those of the author's and do not necessarily reflect the official policy or position of M3 India.

The author is a practising super specialist from New Delhi.